View ValuationLavipharm 将来の成長Future 基準チェック /06現在、 Lavipharmの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長10.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updates分析記事 • May 01Earnings Troubles May Signal Larger Issues for Lavipharm (ATH:LAVI) ShareholdersLavipharm S.A.'s ( ATH:LAVI ) recent weak earnings report didn't cause a big stock movement. We think that investors...Reported Earnings • Apr 29Full year 2025 earnings released: EPS: €0.03 (vs €0.052 in FY 2024)Full year 2025 results: EPS: €0.03 (down from €0.052 in FY 2024). Revenue: €62.6m (up 18% from FY 2024). Net income: €5.05m (down 42% from FY 2024). Profit margin: 8.1% (down from 16% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Apr 09Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €1.42, the stock trades at a trailing P/E ratio of 47.4x. Average trailing P/E is 21x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 253% over the past three years.Reported Earnings • Mar 20Full year 2025 earnings releasedFull year 2025 results: Revenue: €62.6m (up 18% from FY 2024). Net income: €5.05m (down 42% from FY 2024). Profit margin: 8.1% (down from 16% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 44% per year, which means it is well ahead of earnings.お知らせ • Mar 06+ 2 more updatesLavipharm S.A. to Report Fiscal Year 2025 Results on Apr 23, 2026Lavipharm S.A. announced that they will report fiscal year 2025 results at 5:20 PM, GTB Standard Time on Apr 23, 2026分析記事 • Jan 28Even With A 27% Surge, Cautious Investors Are Not Rewarding Lavipharm S.A.'s (ATH:LAVI) Performance CompletelyDespite an already strong run, Lavipharm S.A. ( ATH:LAVI ) shares have been powering on, with a gain of 27% in the last...New Risk • Jan 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Greek stocks, typically moving 5.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.7x net interest cover). Minor Risks Share price has been volatile over the past 3 months (5.3% average weekly change). Profit margins are more than 30% lower than last year (3.8% net profit margin).分析記事 • Dec 18Lavipharm (ATH:LAVI) Takes On Some Risk With Its Use Of DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...New Risk • Nov 26New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.7x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.7x net interest cover). Dividend is not well covered by earnings and cash flows. Payout ratio: 172% Paying a dividend despite having no free cash flows. Minor Risk Profit margins are more than 30% lower than last year (3.8% net profit margin).Upcoming Dividend • Jul 10Inaugural dividend of €0.02 per shareEligible shareholders must have bought the stock before 17 July 2025. Payment date: 24 July 2025. This is the first dividend for Lavipharm since going public. The average dividend yield among industry peers is 2.8%.分析記事 • Apr 10We Think Shareholders Should Be Aware Of Some Factors Beyond Lavipharm's (ATH:LAVI) ProfitThe latest earnings release from Lavipharm S.A. ( ATH:LAVI ) disappointed investors. We did some digging and found some...Reported Earnings • Apr 08Full year 2024 earnings released: EPS: €0.052 (vs €0.012 in FY 2023)Full year 2024 results: EPS: €0.052 (up from €0.012 in FY 2023). Revenue: €52.9m (up 11% from FY 2023). Net income: €8.67m (up 340% from FY 2023). Profit margin: 16% (up from 4.1% in FY 2023). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings.New Risk • Mar 28New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.9x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.9x net interest cover). Minor Risk Share price has been volatile over the past 3 months (4.8% average weekly change).お知らせ • Mar 15Lavipharm S.A., Annual General Meeting, Jul 03, 2025Lavipharm S.A., Annual General Meeting, Jul 03, 2025.New Risk • Dec 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Greek stocks, typically moving 4.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (4.4% average weekly change). Large one-off items impacting financial results.お知らせ • Nov 01Lavipharm S.A. to Report Nine Months, 2024 Results on Nov 14, 2024Lavipharm S.A. announced that they will report nine months, 2024 results on Nov 14, 2024分析記事 • Sep 26Lavipharm's (ATH:LAVI) Earnings Aren't As Good As They AppearDespite posting strong earnings, Lavipharm S.A.'s ( ATH:LAVI ) stock didn't move much over the last week. We looked...Reported Earnings • Sep 20Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €13.1m (down 16% from 2Q 2023). Net income: €6.63m (up 307% from 2Q 2023). Profit margin: 50% (up from 10% in 2Q 2023).お知らせ • Sep 02Lavipharm S.A. to Report First Half, 2024 Results on Sep 19, 2024Lavipharm S.A. announced that they will report first half, 2024 results on Sep 19, 2024分析記事 • Aug 06Some Shareholders Feeling Restless Over Lavipharm S.A.'s (ATH:LAVI) P/E RatioWith a price-to-earnings (or "P/E") ratio of 61.9x Lavipharm S.A. ( ATH:LAVI ) may be sending very bearish signals at...New Risk • May 29New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.3x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.3x net interest cover). Minor Risk Large one-off items impacting financial results.お知らせ • May 01Lavipharm S.A. to Report Q1, 2024 Results on May 23, 2024Lavipharm S.A. announced that they will report Q1, 2024 results at 5:20 PM, GTB Standard Time on May 23, 2024New Risk • Apr 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Greek stocks, typically moving 4.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Reported Earnings • Mar 05Full year 2023 earnings releasedFull year 2023 results: Revenue: €50.9m (up 11% from FY 2022). Net income: €2.00m (up 139% from FY 2022). Profit margin: 3.9% (up from 1.8% in FY 2022). The increase in margin was driven by higher revenue.お知らせ • Mar 01Lavipharm S.A. to Report Fiscal Year 2023 Results on Mar 21, 2024Lavipharm S.A. announced that they will report fiscal year 2023 results on Mar 21, 2024Reported Earnings • Nov 10Third quarter 2023 earnings released: €0.001 loss per share (vs €0.021 loss in 3Q 2022)Third quarter 2023 results: €0.001 loss per share (improved from €0.021 loss in 3Q 2022). Revenue: €11.7m (down 5.6% from 3Q 2022). Net loss: €118.0k (loss narrowed 78% from 3Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 51 percentage points per year, which is a significant difference in performance.お知らせ • Nov 01Lavipharm S.A. to Report Nine Months, 2023 Results on Nov 08, 2023Lavipharm S.A. announced that they will report nine months, 2023 results on Nov 08, 2023分析記事 • Nov 01Here's Why Lavipharm (ATH:LAVI) Has A Meaningful Debt BurdenHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Reported Earnings • Sep 24Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: €15.6m (up 52% from 2Q 2022). Net income: €1.63m (up 63% from 2Q 2022). Profit margin: 10% (in line with 2Q 2022).お知らせ • Sep 01Lavipharm S.A. to Report First Half, 2024 Results on Sep 21, 2023Lavipharm S.A. announced that they will report first half, 2024 results on Sep 21, 2023Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Sep 17First half 2022 earnings released: EPS: €0.037 (vs €0.15 in 1H 2021)First half 2022 results: EPS: €0.037 (down from €0.15 in 1H 2021). Revenue: €21.2m (up 8.4% from 1H 2021). Net income: €1.90m (down 27% from 1H 2021). Profit margin: 9.0% (down from 13% in 1H 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings.お知らせ • Aug 09Lavipharm S.A., Annual General Meeting, Aug 30, 2022Lavipharm S.A., Annual General Meeting, Aug 30, 2022.Valuation Update With 7 Day Price Move • Aug 01Investor sentiment improved over the past weekAfter last week's 19% share price gain to €1.39, the stock trades at a trailing P/E ratio of 13.7x. Average trailing P/E is 18x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 64% over the past three years.お知らせ • Jun 01Lavipharm S.A., Annual General Meeting, Jun 30, 2022Lavipharm S.A., Annual General Meeting, Jun 30, 2022.Buying Opportunity • May 26Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 25%. The fair value is estimated to be €0.57, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.5% over the last 3 years, while earnings per share has been flat.Buying Opportunity • May 06Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 36%. The fair value is estimated to be €0.57, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.5% over the last 3 years, while earnings per share has been flat.Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (4 non-independent directors). Executive Director Telemaque Lavidas is the most experienced director on the board, commencing their role in 2019. Independent Non Executive Director James Christopoulos was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Oct 03First half 2021 earnings released: EPS €0.051 (vs €0.042 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €19.6m (up 7.1% from 1H 2020). Net income: €2.60m (up 20% from 1H 2020). Profit margin: 13% (up from 12% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year whereas the company’s share price has increased by 49% per year.Reported Earnings • May 02Full year 2020 earnings released: EPS €0.042 (vs €0.10 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: €37.6m (up 12% from FY 2019). Net income: €2.17m (down 59% from FY 2019). Profit margin: 5.8% (down from 16% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 46% per year, which means it is well ahead of earnings.分析記事 • Feb 11We're Not Counting On Lavipharm (ATH:LAVI) To Sustain Its Statutory ProfitabilityBroadly speaking, profitable businesses are less risky than unprofitable ones. However, sometimes companies receive a...Is New 90 Day High Low • Nov 11New 90-day high: €0.40The company is up 38% from its price of €0.29 on 13 August 2020. The Greek market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 3.0% over the same period.Is New 90 Day High Low • Oct 08New 90-day high: €0.37The company is up 29% from its price of €0.29 on 10 July 2020. The Greek market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 4.0% over the same period.Reported Earnings • Oct 01First half earnings releasedOver the last 12 months the company has reported total profits of €6.88m, up 397% from the prior year. Total revenue was €35.7m over the last 12 months, up 5.8% from the prior year. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Lavipharm は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測ATSE:LAVI - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202563527N/A9/30/2025552N/AN/AN/A6/30/2025552-61N/A3/31/2025539N/AN/AN/A12/31/2024539-54N/A9/30/2024469N/AN/AN/A6/30/2024478-42N/A3/31/2024522N/AN/AN/A12/31/2023482-40N/A9/30/2023540N/AN/AN/A6/30/2023441-342N/A3/31/2023491N/AN/AN/A12/31/2022391-323N/A9/30/2022432N/AN/AN/A6/30/202241135N/A3/31/2022411N/AN/AN/A12/31/202140224N/A9/30/202139223N/A6/30/202139313N/A3/31/202138213N/A12/31/202038213N/A9/30/202037413N/A6/30/202036714N/A3/31/202035613N/A12/31/201934503N/A9/30/2019343N/A2N/A6/30/2019341N/A1N/A3/31/2019341N/A1N/A12/31/2018341N/A1N/A9/30/2018330N/A2N/A6/30/201832-1N/A2N/A3/31/2018326N/A2N/A12/31/20173213N/A2N/A9/30/20173211N/A1N/A6/30/20173210N/A1N/A3/31/2017327N/A1N/A12/31/2016314N/A1N/A9/30/2016314N/A1N/A6/30/2016284N/A1N/A3/31/201627-2N/A0N/A12/31/201526-7N/A1N/A9/30/201527-9N/A1N/A6/30/201529-9N/A2N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: LAVIの予測収益成長が 貯蓄率 ( 3.2% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: LAVIの収益がGreek市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: LAVIの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: LAVIの収益がGreek市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: LAVIの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: LAVIの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 15:28終値2026/05/21 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Lavipharm S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
分析記事 • May 01Earnings Troubles May Signal Larger Issues for Lavipharm (ATH:LAVI) ShareholdersLavipharm S.A.'s ( ATH:LAVI ) recent weak earnings report didn't cause a big stock movement. We think that investors...
Reported Earnings • Apr 29Full year 2025 earnings released: EPS: €0.03 (vs €0.052 in FY 2024)Full year 2025 results: EPS: €0.03 (down from €0.052 in FY 2024). Revenue: €62.6m (up 18% from FY 2024). Net income: €5.05m (down 42% from FY 2024). Profit margin: 8.1% (down from 16% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Apr 09Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €1.42, the stock trades at a trailing P/E ratio of 47.4x. Average trailing P/E is 21x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 253% over the past three years.
Reported Earnings • Mar 20Full year 2025 earnings releasedFull year 2025 results: Revenue: €62.6m (up 18% from FY 2024). Net income: €5.05m (down 42% from FY 2024). Profit margin: 8.1% (down from 16% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 44% per year, which means it is well ahead of earnings.
お知らせ • Mar 06+ 2 more updatesLavipharm S.A. to Report Fiscal Year 2025 Results on Apr 23, 2026Lavipharm S.A. announced that they will report fiscal year 2025 results at 5:20 PM, GTB Standard Time on Apr 23, 2026
分析記事 • Jan 28Even With A 27% Surge, Cautious Investors Are Not Rewarding Lavipharm S.A.'s (ATH:LAVI) Performance CompletelyDespite an already strong run, Lavipharm S.A. ( ATH:LAVI ) shares have been powering on, with a gain of 27% in the last...
New Risk • Jan 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Greek stocks, typically moving 5.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.7x net interest cover). Minor Risks Share price has been volatile over the past 3 months (5.3% average weekly change). Profit margins are more than 30% lower than last year (3.8% net profit margin).
分析記事 • Dec 18Lavipharm (ATH:LAVI) Takes On Some Risk With Its Use Of DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
New Risk • Nov 26New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.7x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.7x net interest cover). Dividend is not well covered by earnings and cash flows. Payout ratio: 172% Paying a dividend despite having no free cash flows. Minor Risk Profit margins are more than 30% lower than last year (3.8% net profit margin).
Upcoming Dividend • Jul 10Inaugural dividend of €0.02 per shareEligible shareholders must have bought the stock before 17 July 2025. Payment date: 24 July 2025. This is the first dividend for Lavipharm since going public. The average dividend yield among industry peers is 2.8%.
分析記事 • Apr 10We Think Shareholders Should Be Aware Of Some Factors Beyond Lavipharm's (ATH:LAVI) ProfitThe latest earnings release from Lavipharm S.A. ( ATH:LAVI ) disappointed investors. We did some digging and found some...
Reported Earnings • Apr 08Full year 2024 earnings released: EPS: €0.052 (vs €0.012 in FY 2023)Full year 2024 results: EPS: €0.052 (up from €0.012 in FY 2023). Revenue: €52.9m (up 11% from FY 2023). Net income: €8.67m (up 340% from FY 2023). Profit margin: 16% (up from 4.1% in FY 2023). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings.
New Risk • Mar 28New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.9x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.9x net interest cover). Minor Risk Share price has been volatile over the past 3 months (4.8% average weekly change).
お知らせ • Mar 15Lavipharm S.A., Annual General Meeting, Jul 03, 2025Lavipharm S.A., Annual General Meeting, Jul 03, 2025.
New Risk • Dec 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Greek stocks, typically moving 4.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (4.4% average weekly change). Large one-off items impacting financial results.
お知らせ • Nov 01Lavipharm S.A. to Report Nine Months, 2024 Results on Nov 14, 2024Lavipharm S.A. announced that they will report nine months, 2024 results on Nov 14, 2024
分析記事 • Sep 26Lavipharm's (ATH:LAVI) Earnings Aren't As Good As They AppearDespite posting strong earnings, Lavipharm S.A.'s ( ATH:LAVI ) stock didn't move much over the last week. We looked...
Reported Earnings • Sep 20Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €13.1m (down 16% from 2Q 2023). Net income: €6.63m (up 307% from 2Q 2023). Profit margin: 50% (up from 10% in 2Q 2023).
お知らせ • Sep 02Lavipharm S.A. to Report First Half, 2024 Results on Sep 19, 2024Lavipharm S.A. announced that they will report first half, 2024 results on Sep 19, 2024
分析記事 • Aug 06Some Shareholders Feeling Restless Over Lavipharm S.A.'s (ATH:LAVI) P/E RatioWith a price-to-earnings (or "P/E") ratio of 61.9x Lavipharm S.A. ( ATH:LAVI ) may be sending very bearish signals at...
New Risk • May 29New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.3x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.3x net interest cover). Minor Risk Large one-off items impacting financial results.
お知らせ • May 01Lavipharm S.A. to Report Q1, 2024 Results on May 23, 2024Lavipharm S.A. announced that they will report Q1, 2024 results at 5:20 PM, GTB Standard Time on May 23, 2024
New Risk • Apr 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Greek stocks, typically moving 4.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Reported Earnings • Mar 05Full year 2023 earnings releasedFull year 2023 results: Revenue: €50.9m (up 11% from FY 2022). Net income: €2.00m (up 139% from FY 2022). Profit margin: 3.9% (up from 1.8% in FY 2022). The increase in margin was driven by higher revenue.
お知らせ • Mar 01Lavipharm S.A. to Report Fiscal Year 2023 Results on Mar 21, 2024Lavipharm S.A. announced that they will report fiscal year 2023 results on Mar 21, 2024
Reported Earnings • Nov 10Third quarter 2023 earnings released: €0.001 loss per share (vs €0.021 loss in 3Q 2022)Third quarter 2023 results: €0.001 loss per share (improved from €0.021 loss in 3Q 2022). Revenue: €11.7m (down 5.6% from 3Q 2022). Net loss: €118.0k (loss narrowed 78% from 3Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 51 percentage points per year, which is a significant difference in performance.
お知らせ • Nov 01Lavipharm S.A. to Report Nine Months, 2023 Results on Nov 08, 2023Lavipharm S.A. announced that they will report nine months, 2023 results on Nov 08, 2023
分析記事 • Nov 01Here's Why Lavipharm (ATH:LAVI) Has A Meaningful Debt BurdenHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Reported Earnings • Sep 24Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: €15.6m (up 52% from 2Q 2022). Net income: €1.63m (up 63% from 2Q 2022). Profit margin: 10% (in line with 2Q 2022).
お知らせ • Sep 01Lavipharm S.A. to Report First Half, 2024 Results on Sep 21, 2023Lavipharm S.A. announced that they will report first half, 2024 results on Sep 21, 2023
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Sep 17First half 2022 earnings released: EPS: €0.037 (vs €0.15 in 1H 2021)First half 2022 results: EPS: €0.037 (down from €0.15 in 1H 2021). Revenue: €21.2m (up 8.4% from 1H 2021). Net income: €1.90m (down 27% from 1H 2021). Profit margin: 9.0% (down from 13% in 1H 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings.
お知らせ • Aug 09Lavipharm S.A., Annual General Meeting, Aug 30, 2022Lavipharm S.A., Annual General Meeting, Aug 30, 2022.
Valuation Update With 7 Day Price Move • Aug 01Investor sentiment improved over the past weekAfter last week's 19% share price gain to €1.39, the stock trades at a trailing P/E ratio of 13.7x. Average trailing P/E is 18x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 64% over the past three years.
お知らせ • Jun 01Lavipharm S.A., Annual General Meeting, Jun 30, 2022Lavipharm S.A., Annual General Meeting, Jun 30, 2022.
Buying Opportunity • May 26Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 25%. The fair value is estimated to be €0.57, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.5% over the last 3 years, while earnings per share has been flat.
Buying Opportunity • May 06Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 36%. The fair value is estimated to be €0.57, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.5% over the last 3 years, while earnings per share has been flat.
Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (4 non-independent directors). Executive Director Telemaque Lavidas is the most experienced director on the board, commencing their role in 2019. Independent Non Executive Director James Christopoulos was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Oct 03First half 2021 earnings released: EPS €0.051 (vs €0.042 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €19.6m (up 7.1% from 1H 2020). Net income: €2.60m (up 20% from 1H 2020). Profit margin: 13% (up from 12% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year whereas the company’s share price has increased by 49% per year.
Reported Earnings • May 02Full year 2020 earnings released: EPS €0.042 (vs €0.10 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: €37.6m (up 12% from FY 2019). Net income: €2.17m (down 59% from FY 2019). Profit margin: 5.8% (down from 16% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 46% per year, which means it is well ahead of earnings.
分析記事 • Feb 11We're Not Counting On Lavipharm (ATH:LAVI) To Sustain Its Statutory ProfitabilityBroadly speaking, profitable businesses are less risky than unprofitable ones. However, sometimes companies receive a...
Is New 90 Day High Low • Nov 11New 90-day high: €0.40The company is up 38% from its price of €0.29 on 13 August 2020. The Greek market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 3.0% over the same period.
Is New 90 Day High Low • Oct 08New 90-day high: €0.37The company is up 29% from its price of €0.29 on 10 July 2020. The Greek market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 4.0% over the same period.
Reported Earnings • Oct 01First half earnings releasedOver the last 12 months the company has reported total profits of €6.88m, up 397% from the prior year. Total revenue was €35.7m over the last 12 months, up 5.8% from the prior year.